Rare cancer survival predictor developed
NCT ID NCT07179341
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looked at 156 patients with thymic carcinoma, a rare and aggressive chest cancer. Researchers created a tool called a nomogram that uses patient data to predict how long someone might live after diagnosis. The tool was tested on three groups of patients and showed promise in estimating survival, but it needs more research before it can be used in clinics.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this tool could help doctors better predict survival for thymic carcinoma patients, guiding treatment decisions.
- What could go wrong
- This is a small, single-center study based on past data. The tool needs testing in larger, diverse groups before it can be widely used.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
156 people
The number who actually took part.
- Started
-
Jul 2024
- Finished
-
Aug 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The diagnosis of TC in patients should be confirmed through endoscopic tumor biopsy or surgery to obtain tumor tissue for pathological confirmation under light microscope, and even further confirmed through immunohistochemical staining. * Patients should accept surgery and obtain complete postoperative pathological reports in order to assess Masaoka-Koga staging. * Patients who accepted surgery should be followed up at least six months or reached the endpoint event. Exclusion Criteria: * The patient had two types of primary tumors concurrently including TC. * The tumor in the thymus was not primary but metastatic, having originated from a different primary site. * The patient did not obtain a complete pathological report after surgery.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Thymic carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
651 Dongfeng Road East, Yuexiu District, Guangzhou, P.R. China
Guangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug chemo combo outsmart resistant tumors?
- Shorter radiation after thymic tumor surgery may cut side effects
- Fewer radiation sessions may be just as effective for thymic tumors after surgery
- Immune cells engineered to hunt thymus cancer show promise in early trial
- Immunotherapy drug nivolumab tested for rare thymus cancers
- New combo therapy shows promise for rare chest cancer